Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68GA-NOTA-E(PEG4-TMVP1)2
- Development stage
- Unknown
- Lead developer
- Tongji Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
A radiolabeled homodimeric peptide tracer designed for positron emission tomography (PET), 68GA-NOTA-E(PEG4-TMVP1)2 consists of two TMVP1 peptides conjugated via a tetraethyleneglycol (PEG4) linker and chelated with NOTA to gallium-68. TMVP1 is a peptide that binds specifically to vascular endothelial growth factor receptor 3 (VEGFR-3), which is highly expressed in tumor lymphangiogenesis and certain cancers. The radiotracer demonstrates high affinity for VEGFR-3, rapid renal excretion, high tumor uptake, and favorable safety in both healthy volunteers and cancer patients. It has been evaluated primarily for imaging VEGFR-3 expression in cervical cancer but also investigated in ovarian, breast, and lung cancers[1][2][7].
- Other names
- [68Ga]Ga-NOTA-(TMVP1)268GA-NOTA-E(PEG4-TMVP1)2
02
Targets
VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on 68GA-NOTA-E(PEG4-TMVP1)2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68GA-NOTA-E(PEG4-TMVP1)2.